Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ARF6 | P62330 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19810310 | 0.91 | ADORA2B (0.38) | MEN1KMT2APOLBHTTADORA2A | |
| SCHEMBL2670126 | 0.91 | ALDH1A1 (0.39) | MEN1KMT2APOLBHTTADORA2A | |
| SCHEMBL28888591 | 0.88 | PSD (0.38) | MEN1KMT2APOLBHTTADORA2A | |
| SCHEMBL5560844 | 0.88 | ALDH1A1 (0.37) | KMT2AADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL19810320 | 0.88 | LTB4R (0.36) | MEN1KMT2APOLBHTTADORA2A | |
| SCHEMBL28391210 | 0.88 | PRNP (0.36) | MEN1KMT2ACYP2C9CYP2C19ADORA2A | |
| SCHEMBL19810212 | 0.88 | ALDH1A1 (0.38) | MEN1KMT2APOLBHTTADORA2A | |
| SCHEMBL19810266 | 0.87 | ALDH1A1 (0.36) | MEN1KMT2ACYP2C9CYP2C19POLB | |
| SCHEMBL28394541 | 0.87 | ADORA2B (0.35) | MEN1KMT2APOLBHTTADORA2A | |
| SCHEMBL25781925 | 0.87 | ADORA2B (0.35) | MEN1KMT2APOLBHTTADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669280-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2020-06-02 | — | — | US | claimed |
| US-10000500-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2018-06-19 | — | — | US | claimed |
| US-20180030059-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-02-01 | — | — | US | claimed |
| EP-3490991-B1 | COELENTERAZINE ANALOGUES | PROMEGA CORP (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3490991-B1 | COELENTERAZINE ANALOGUES | PROMEGA CORP (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10669280-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669280-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-10428075-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428075-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180334463-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-11-22 | — | — | US | disclosed |
| US-10000500-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000500-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180030059-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-02-01 | — | — | US | disclosed |
| US-20180030059-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000500-B2 | Coelenterazine analogues | GLB1, TCF7L2, SI | MEN1 1874/4885KMT2A 2198/4885CYP2C9 2418/4885 |
| US-10669280-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | MEN1 1826/4885KMT2A 2122/4885CYP2C9 2156/4885 |
| US-10428075-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | MEN1 1826/4885KMT2A 2122/4885CYP2C9 2156/4885 |
| US-20180030059-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | MEN1 1826/4885KMT2A 2122/4885CYP2C9 2156/4885 |
| US-20180334463-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | MEN1 1826/4885KMT2A 2122/4885CYP2C9 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.